Screener
Syndax Pharmaceuticals SNDX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $10,843 | $16,580 |
| Accrued expenses and other current liabilities | 74,843 | 103,064 |
| Current portion of right-of-use liability | 487 | 470 |
| Current portion of capital lease | 1 | 2 |
| Total current liabilities | 86,174 | 120,116 |
| Long-term liabilities: |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's accrued expenses?
- Syndax Pharmaceuticals (SNDX) reported accrued expenses of $74.84M in Q1 2026.
- How has Syndax Pharmaceuticals's accrued expenses changed year-over-year?
- Syndax Pharmaceuticals's accrued expenses increased by 33.7% year-over-year, from $55.98M to $74.84M.
- What is the long-term trend for Syndax Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's accrued expenses has grown at a 33.5% compound annual growth rate (CAGR), from $24.28M to $103.06M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Syndax Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude